{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.43","value":"127.40"},{"groupId":"OG001","spread":"22.16","value":"128.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"559"}],"units":"Participants"}],"title":"Total Score, Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.01","value":"1.98"},{"groupId":"OG001","spread":"17.12","value":"3.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"499"},{"groupId":"OG001","value":"484"}],"units":"Participants"}],"title":"Total Score Change, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.75","value":"4.18"},{"groupId":"OG001","spread":"20.03","value":"5.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"471"},{"groupId":"OG001","value":"471"}],"units":"Participants"}],"title":"Total Score Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.16","value":"8.40"},{"groupId":"OG001","spread":"19.80","value":"8.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"392"}],"units":"Participants"}],"title":"Total Score Change, Maint Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.31","value":"8.87"},{"groupId":"OG001","spread":"19.55","value":"7.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"396"}],"units":"Participants"}],"title":"Total Score Change, Maint Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.88","value":"7.43"},{"groupId":"OG001","spread":"20.57","value":"8.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"401"},{"groupId":"OG001","value":"433"}],"units":"Participants"}],"title":"Total Score Change, End Maint"}],"denoms":[{"counts":[{"groupId":"OG000","value":"552"},{"groupId":"OG001","value":"559"}],"units":"Participants"}],"description":"The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants received either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"MEAN","populationDescription":"The FL ITT population was defined as all randomized participants with follicular histology grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)","type":"SECONDARY","unitOfMeasure":"units on a scale"}